SCHEMBL2054711

SCHEMBL2054711

Cn1cc(S(=O)(=O)c2ccc(C=O)cc2)nn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.36
TRIM24 O15164 1/20 0.35
TRIM33 Q9UPN9 1/20 0.35
NR1I2 O75469 3/20 0.34
KDM4E B2RXH2 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HTR2A P28223 1/20 0.34
KCNH2 Q12809 1/20 0.34
CYP2A6 P11509 3/20 0.33
KCNJ1 P48048 1/20 0.33
NLRP3 Q96P20 1/20 0.32
KDM4A O75164 1/20 0.31
KDM5C P41229 1/20 0.31
KDM4C Q9H3R0 1/20 0.31
KDM2A Q9Y2K7 1/20 0.31
KDM3A Q9Y4C1 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
STS P08842 1/20 0.31
TYR P14679 1/20 0.31
MMP1 P03956 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8250024 0.80 HTR6 (0.45) ALDH1A1KDM4ESMN1; SMN2
SCHEMBL2054695 0.77 MAOA (0.39) NR1I2HTR2A
SCHEMBL6853680 0.71 ALDH1A1 (0.48) ALDH1A1TRIM24TRIM33KDM4ECYP2A6
SCHEMBL2096000 0.71 FPR2 (0.39) ALDH1A1KDM4EHTR2A
SCHEMBL22307513 0.67 NLRP3 (0.47) ALDH1A1NR1I2SMN1; SMN2NLRP3
SCHEMBL14837628 0.66 KAT6A (0.33) ALDH1A1
SCHEMBL2029529 0.66 GAA (0.70) ALDH1A1SMN1; SMN2CYP2A6MMP1MMP2
SCHEMBL22307512 0.66 NLRP3 (0.48) ALDH1A1NR1I2SMN1; SMN2NLRP3
SCHEMBL6854376 0.65 STS (0.52) ALDH1A1KDM4ESMN1; SMN2CYP2A6STS
SCHEMBL22308263 0.65 GAA (0.48) ALDH1A1NR1I2NLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899294-B1 THERAPEUTIC AGENTS MERCK SHARP & DOHME (GB) 2015-03-18 EP disclosed
US-8163956-B2 Inhibitors of GLYT1 transporters MERCK SHARP & DOHME CORP. (US) 2012-04-24 US disclosed
US-8163956-B2 Inhibitors of GLYT1 transporters MERCK SHARP & DOHME CORP. (US) 2012-04-24 US disclosed
US-8163956-B2 Inhibitors of GLYT1 transporters MERCK SHARP & DOHME CORP. (US) 2012-04-24 US disclosed
US-20090286765-A1 Therapeutic Agents MERCK SHARP & DOHME (UK) LIMITED (GB) 2009-11-19 US disclosed
US-20090286765-A1 Therapeutic Agents MERCK SHARP & DOHME (UK) LIMITED (GB) 2009-11-19 US disclosed
US-20090286765-A1 Therapeutic Agents MERCK SHARP & DOHME (UK) LIMITED (GB) 2009-11-19 US disclosed
WO-2006134341-A1 THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286765-A1 Therapeutic Agents GRIA1, GRIN1, GLRA1 ALDH1A1 652/4885TRIM24 3621/4885TRIM33 4812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.